Gabelli Funds’s Lucid Diagnostics LUCD Stock Holding History

Gabelli Funds’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.4K	Hold	19,500	–	–	﹤0.01%	1240
2025 Q4	$21.3K	Buy	+19,500	New	+$21.8K	﹤0.01%	1226

Other funds holding LUCD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Gabelli Funds's LUCD Position: Q1 2026 in Review

Gabelli Funds held its Lucid Diagnostics (LUCD) position steady in Q1 2026 at 19,500 shares worth $22.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1240.

Gabelli Funds first reported a position in LUCD in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

Gabelli Funds held 19,500 shares of Lucid Diagnostics worth $22.4K as of Q1 2026.
Gabelli Funds left its Lucid Diagnostics share count unchanged in Q1 2026.
Lucid Diagnostics made up ﹤0.01% of Gabelli Funds's portfolio in Q1 2026, its #1240 holding.
Gabelli Funds first reported a position in Lucid Diagnostics in Q4 2025 and has held it in 2 quarters since.
103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Gabelli Funds's 13F filing for Q1 2026, filed 14 May 2026.